A
Andrea Decensi
Researcher at University of Genoa
Publications - 92
Citations - 4483
Andrea Decensi is an academic researcher from University of Genoa. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 92 publications receiving 4038 citations. Previous affiliations of Andrea Decensi include Westmead Hospital & Ente Ospedaliero Ospedali Galliera.
Papers
More filters
Journal ArticleDOI
Phase II study of navelbine in advanced renal cell carcinoma.
Luciano Canobbio,Francesco Boccardo,Domenico Guarneri,Caterina Calabria,Andrea Decensi,Antonio Curotto,G. Martorana,Luciano Giuliani +7 more
Journal ArticleDOI
A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma
Matteo Puntoni,Daniela Branchi,Alessandra Argusti,Silvia Zanardi,Cristiano Crosta,Emanuele Meroni,Francesco Munizzi,Paolo Michetti,Gianni Coccia,Giuseppe De Roberto,Roberto Bandelloni,Laura Turbino,Egle Minetti,Marco Mori,Sandra Salvi,Simona Boccardo,Beatrice Gatteschi,Roberto Benelli,Angelica Sonzogni,Andrea Decensi +19 more
TL;DR: Allopurinol can inhibit biomarkers of oxidative activation in colon adenomatous polyps and normal adjacent tissue, and further studies should define its potential chemopreventive activity.
Journal ArticleDOI
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Francesco Boccardo,Andrea Decensi,Domenico Guarneri,Alessandra Rubagotti,F. Oneto,G. Martorana,Luciano Giuliani,Delli Ponti U,S. Petracco,Pietro Cortellini +9 more
TL;DR: The results do suggest, however, that there is no particular advantage in using a combination of Zoladex plus flutamide compared to addingFlutamide on failure of treatment with ZolADEx alone, and follow-up time is short.
Journal ArticleDOI
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Federica Grosso,Lorenzo D'Ambrosio,Massimo Zucchetti,Toni Ibrahim,Stefano Tamberi,Cristina Matteo,Eliana Rulli,D. Comandini,Emanuela Palmerini,Giacomo Giulio Baldi,Andrea Decensi,Marina Bergaglio,Domenico Marra,Emanuela Marchesi,Giacomo Siri,Maurizio D'Incalci,Giovanni Grignani +16 more
TL;DR: Although elderly patients (≥70 years) represent 30% of new diagnoses of soft tissue sarcoma (STS), they are underrepresented in clinical trials and are often unfit to receive standard anthracycline‐based chemotherapy.
Journal ArticleDOI
Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer
TL;DR: In this article, the activity of pure non-steroidal antiandrogen nilutamide as a single agent was evaluated in 44 patients with metastatic carcinoma of the prostate.